Bank Pictet & Cie Europe AG Sells 3,510 Shares of Thermo Fisher Scientific Inc. $TMO

Bank Pictet & Cie Europe AG decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 36,194 shares of the medical research company’s stock after selling 3,510 shares during the period. Bank Pictet & Cie Europe AG’s holdings in Thermo Fisher Scientific were worth $17,555,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. TIAA Trust National Association grew its stake in Thermo Fisher Scientific by 10.5% during the 2nd quarter. TIAA Trust National Association now owns 123,948 shares of the medical research company’s stock worth $50,256,000 after buying an additional 11,817 shares during the last quarter. Lombard Odier Asset Management Switzerland SA boosted its holdings in Thermo Fisher Scientific by 8.4% in the second quarter. Lombard Odier Asset Management Switzerland SA now owns 14,490 shares of the medical research company’s stock worth $5,875,000 after acquiring an additional 1,128 shares in the last quarter. Caledonia Investments PLC increased its holdings in shares of Thermo Fisher Scientific by 11.5% during the second quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company’s stock valued at $45,299,000 after acquiring an additional 11,500 shares in the last quarter. Weaver Capital Management LLC acquired a new stake in Thermo Fisher Scientific in the 3rd quarter worth approximately $506,000. Finally, Heritage Investors Management Corp grew its position in Thermo Fisher Scientific by 9.6% during the 2nd quarter. Heritage Investors Management Corp now owns 56,587 shares of the medical research company’s stock worth $22,944,000 after purchasing an additional 4,971 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.7%

Shares of TMO opened at $579.42 on Friday. The company has a market capitalization of $217.69 billion, a price-to-earnings ratio of 33.47, a PEG ratio of 4.12 and a beta of 0.91. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The stock’s 50-day moving average price is $575.60 and its 200-day moving average price is $507.61. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The company had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.Thermo Fisher Scientific’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the previous year, the company posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be given a $0.43 dividend. The ex-dividend date is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is 9.94%.

Thermo Fisher Scientific declared that its board has initiated a stock buyback plan on Thursday, November 6th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Morgan Stanley lifted their price objective on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Citigroup raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $580.00 to $660.00 in a research report on Thursday, December 11th. Leerink Partners increased their price objective on Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday, October 22nd. UBS Group lifted their target price on Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Finally, Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $616.60.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 7,250 shares of the firm’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $566.10, for a total transaction of $4,104,225.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at $64,400,668.20. This trade represents a 5.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael D. Shafer sold 10,725 shares of the company’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total value of $6,435,000.00. Following the completion of the transaction, the executive vice president directly owned 18,731 shares of the company’s stock, valued at $11,238,600. The trade was a 36.41% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 149,271 shares of company stock worth $86,507,282. 0.33% of the stock is currently owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.